Galmed Pharmaceuticals (GLMD) Free Cash Flow (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Free Cash Flow of -$2.5 million for Q1 2026, down 117.31% year-over-year from $14.7 million in Q1 2025, and down 192.45% quarter-over-quarter from $2.7 million in Q4 2025.
Galmed Pharmaceuticals (GLMD) Free Cash Flow (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Free Cash Flow history runs 14 years deep, the most recent figure standing at -$2.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 117.31% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$3.0 million (down 116.16% YoY), while the FY2025 annual figure was -$1.6 million, up 20.9% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$2.5 million, down from $2.7 million in the prior quarter.
- The five-year high for Free Cash Flow was $2.7 million in Q4 2025, with the low at -$11.1 million in Q2 2022.
- The 5-year median for Free Cash Flow is -$1.4 million (2023), against an average of -$1.8 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow slumped 563.14% in 2023, then soared 314.14% in 2024.
- Galmed Pharmaceuticals' Free Cash Flow stood at -$4.0 million in 2022, then soared by 77.72% to -$898000.0 in 2023, then jumped by 314.14% to $1.9 million in 2024, then surged by 42.64% to $2.7 million in 2025, then tumbled by 192.45% to -$2.5 million in 2026.
- Business Quant data shows GLMD's Free Cash Flow at -$2.5 million in Q1 2026, $2.7 million in Q4 2025, and -$1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | -2.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.54 Mn |
| Mar 31, 2026 | -2.54 Mn |
| Dec 31, 2025 | 2.74 Mn |
| Dec 31, 2025 | 2.74 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Jun 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -1.27 Mn |
| Mar 31, 2025 | -1.17 Mn |
| Mar 31, 2025 | -1.17 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -1.02 Mn |
| Jun 30, 2024 | -1.02 Mn |
| Mar 31, 2024 | -1.83 Mn |
| Mar 31, 2024 | -1.83 Mn |
| Dec 31, 2023 | -898,000.00 |
| Dec 31, 2023 | -898,000.00 |